MedPath

Oral Lichen Planus Treatment

Not Applicable
Completed
Conditions
Oral Lichen Planus
Interventions
Radiation: Patients will be treated with localized PBM with a diode laser
Registration Number
NCT05127083
Lead Sponsor
Universidad de Murcia
Brief Summary

Oral lichen planus (OLP) is a chronic inflammatory and immune-mediated disease affecting the oral mucosa. OLP presents with asymptomatic, lacelike white stripes and/or symptomatic red, ulcerated mucous membranes. Eating, drinking and oral hygiene procedures may be painful resulting in reduced quality of life (QOL). Photodynamic therapy (PDT) is a new suggestion for OLP treatment PDT is a successful treatment mo- dality for premalignant and malignant diseases of head and neck,gastrointestinal tract, lung, and skin

In this study, the effect of photodynamic therapy with topical corticosteroid in oral lichen planus patients was compared

Detailed Description

In this study, the efficacy of toluidine blue-mediated photodynamic therapy and topical triamcinolone acetonide 0.2% on decreasing pain and size of OLP lesions was compared.

This randomized, clinical trial compared the therapeutic effect of photodynamic therapy on symptomatic OLP (atrophic/ erosive/ulcerative forms) with triamcinolone acetonide 0.2%. The protocol of the clinical trial, which was conducted according to the ethical principles of Helsinki Group I toluidine blue-mediated photodynamic therapy Group II photodynamic therapy GroupIII laser sham + triamcinolone acetonide 0.2%

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • . The patients with clinical or histopathological diagnosis of bilateral atrophic or erosive OLP (symptomatic OLP) who signed the written consent form were recruited.
Exclusion Criteria
  • Patients with drug-induced or contact lichenoid reactions, patients receiving any treatment for OLP in 2 months prior to the study, pregnant or lactating women, patients with uncontrolled systemic disease, and patients with photosensitivity

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
acetonide triamcinolone 0.2%+shamPatients will be treated with localized PBM with a diode laserPatients will be treated with acetonide triamcinolone 0.2% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the gel in the entire lesion three times/days.The number of points will be variable according to the lesion size.
toluidine blue-mediated photodynamic therapyPatients will be treated with localized PBM with a diode laserThe number of points will be variable according to the lesion size. Patients will be treated with localized PBM with a diode laser with continuous wave +toluidine blue
photodynamic therapy + gelPatients will be treated with localized PBM with a diode laserThe number of points will be variable according to the lesion size.atients will be treated with localized PBM with a diode laser with continuous wave
Primary Outcome Measures
NameTimeMethod
Change Thongprasom sign scoringParticipants will be evaluated at baseline (Day 0) ; day 7: day 14 day and 28 day

a score of 0 for normal healthy mucosa, 1 for lesions with only white striae, 2 for mixed keratotic and atrophic or erythematous lesions \< 1 cm2 in size, 3 for keratotic and atrophic or erythematous lesions more than 1 cm2 in size, 4 for erosive/ulcerative lesions smaller than 1 cm2 , and 5 for erosive/ulcerative lesions larger than 1 cm2

Change Assessment of Pain of OLPParticipants will be evaluated at baseline (Day 0) ; day 7: day 14 day and 28 day

The pain will be assessed by applying a Visual Analog Scale, consisting of a 100-mm line numbered in centimeters, with two closed ends. One end is labeled "0" and the other "100", meaning no pain and terrible pain, respectively. Each patient will be instructed to mark a vertical line according to the best value that matches the intensity of pain during the evaluation.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Lopez-Jornet Pia

🇪🇸

Murcia, N/A = Not Applicable, Spain

© Copyright 2025. All Rights Reserved by MedPath